Jazz制药公司将于2026年1月9日推出关于胃肠癌Zanidatamab的第三阶段试验结果。 Jazz Pharmaceuticals to present Phase 3 trial results for zanidatamab in gastrointestinal cancers on January 9, 2026.

Jazz制药公司将在2026年1月9日主办网播,讨论胃肠癌Zanidatamab试验结果的第三阶段,随后在一次主要的肿瘤会议上作了口头介绍。 Jazz Pharmaceuticals will host a webcast on January 9, 2026, to discuss Phase 3 trial results for zanidatamab in gastrointestinal cancers, following an oral presentation at a major oncology conference. 该公司还将出席1月13日J.P.摩根保健大会,由CEO Renee Gala提供公司最新情况。 The company will also present at the J.P. Morgan Healthcare Conference on January 13, with CEO Renee Gala delivering a corporate update. 该公司的投资者关系网站将提供30天的音频网播和重播。 Audio webcasts and replays will be available on the company’s investor relations website for 30 days. 位于都柏林的Jazz为癌症、癫痫和睡眠紊乱等严重疾病开发治疗方法。 Jazz, based in Dublin, develops treatments for serious conditions including cancer, epilepsy, and sleep disorders.